ClinicalTrials.gg
CompletedNCT03665194Updated Feb 4, 2019

A Study to Investigate the Effects of Cortexolone 17α-propionate (and Its Metabolites) on Healthy Volunteers' Heart

A Phase 1 interventional study of Cortexolone 17α-propionate solution and Placebo in Healthy Volunteers, sponsored by Cassiopea SpA. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-04.

Sponsored by Cassiopea SpA · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This is a randomised, double blind placebo controlled Phase I study which will assess the safety, tolerability and PK of Cortexolone 17α-propionate (and its metabolites), and its effects on the QTc interval when administered as multiple doses to healthy adult volunteers. Volunteers will receive a morning and evening dose (12 hours apart) of 225 mg (3 mL Cortexolone 17α-propionate applied topically as a 7.5 % solution (75 mg in 1 mL), giving a total daily dose of 450 mg (6 mL) per individual.

Read the detailed description

Thirty-two volunteers will be enrolled and evaluated (i.e. complete the study). Subjects will be dosed in four groups of eight (purely for logistical reasons relating to the procedure times expected with dosing and ECG). Volunteers will receive either the active drug or matching placebo in a 3:1 ratio. Therefore within each cohort, six volunteers will receive the active drug and two will receive matching placebo.

Volunteers will be screened within 20 days prior to entering the study on Day -1. Each volunteer will receive verbal and written information followed by signing of the ICF prior to any screening procedures taking place. Volunteers will be admitted to the study unit on Day -1, dosed twice daily on Days 1-3 and once on Day 4 (morning dose only). They will be discharged on Day 6 and will have a telephone follow-up on Day 14. If they report any relevant Adverse Event (AE) they will be invited to attend the unit for an outpatient visit as close to Day 14 as is possible.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • QT/QTc Interval
03

In context

Lead sponsor

Cassiopea SpA is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects ≥18 and ≤40 years at the date of signing which is defined as the beginning of the Screening Period.
  2. Subjects must have a (BMI) between 18.0-25.0 kg/m² inclusive.
  3. Subjects must be bald, have a shaved head, or be willing to have their head shaved.
  4. Female subjects who are either: (a) Non-, e.g. (as defined as amenorrhoea for at least 12 months with no alternative medical cause) or permanently sterile (permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy) OR (b) Childbearing potential AND (if heterosexually active) agree to use at least one form of highly effective as defined below, starting at least one menstrual cycle before first study drug administration and continuing until at least 3 months after the end of the systemic exposure of the study drug.

    Highly effective contraceptive methods for females are as follows:

    • Combined (oestrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation as follows:

      • Oral
      • Intravaginal
      • Transdermal
    • Progestogen-only hormonal contraception associated with inhibition of ovulation as follows: o Oral

      • Injectable
      • Implantable
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion
    • Male partner vasectomised (with documented evidence of azoospermia if possible)
  5. Male subjects, if heterosexually active and with a female partner of childbearing potential or a pregnant or breastfeeding partner, must agree to use barrier contraception (male condom) for the treatment period and for at least three months after the end of the systemic exposure of the study drug. Female partners of male subjects who are of childbearing potential must use one or more forms of highly effective contraception as defined above, starting at least one menstrual cycle before (their male subject's) first study drug administration and continuing until at least three months after the end of their male partner's systemic exposure to the study drug.

    For male subjects who have had a vasectomy (with documented evidence of azoospermia if possible) and agree to use a barrier method (male condom) for the stated time period, no additional contraceptive method is required by their female partner.

  6. Subjects must agree not to donate sperm or ova from the time of the first administration of study medication until 3 months after the end of the systemic exposure of the study drug.
  7. Satisfactory medical assessment with no or relevant abnormalities as determined by medical history, physical examination, vital signs, 12-lead , and clinical laboratory evaluation (haematology, biochemistry, coagulation and urinalysis) that is reasonably likely to interfere with the subject's participation in or ability to complete the study as assessed by the investigator.
  8. Ability to provide written, personally signed, and dated informed consent to participate in the study, in accordance with the ICH Good Clinical Practice (GCP) Guideline E6 (1996) and applicable regulations, before completing any study-related procedures.
  9. An understanding, ability, and willingness to fully comply with study procedures and restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Current or recurrent disease (e.g., cardiovascular, haematological, neurological, endocrine, renal, liver, gastrointestinal, hepatic or other conditions) that could affect the action, absorption, or disposition of Cortexolone 17α-propionate, or could affect clinical assessments or clinical laboratory evaluations.
  2. Current or relevant history of any physical or psychiatric illness that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the product or study procedures.
  3. Any other significant disease or disorder which, in the opinion of the investigator, may put the subject at unacceptable risk because of participation in the study, may influence the result of the study, or may affect the subject's ability to participate in the study.
  4. History of any pathology affecting the skin such as eczema, psoriasis or any skin .
  5. Have tattoos on the scalp or thigh which would affect the area for topical application of the trial drug.
  6. The history or presence of any of the following cardiac conditions: known structural cardiac abnormalities; family history of long syndrome; cardiac syncope or recurrent, idiopathic syncope; exercise related cardiac events.
  7. Any clinically significant abnormalities in rhythm, conduction or morphology of resting or clinically important abnormalities that may interfere with the interpretation of QTc interval changes. This includes subjects with any of the following (at screening, Day -1 or pre-dose of Day 1):

    • Sinus node dysfunction.
    • Clinically significant PR (PQ) interval prolongation.
    • Intermittent second or third degree AV block.
    • Complete bundle branch block.
    • Sustained cardiac arrhythmia's including (but not limited to) atrial fibrillation or supraventricular tachycardia; any symptomatic arrhythmia with the exception of isolated extra systoles.
    • More than 200 ventricular ectopic beats in 24 hours.
    • Ventricular tachycardia (ventricular tachycardia defined as ≥ 3 successive ventricular ectopic beats at a rate of > 120 bpm).
    • Abnormal T wave morphology.
    • QT interval corrected using the Fridericia's formula (QTcF) > 450 ms.
    • Any other ECG abnormalities in the standard 12-lead ECG and 24-hour 12 lead Holter ECG or an equivalent assessment which in the opinion of the investigator will interfere with the ECG analysis.

    Subjects with borderline abnormalities may be included if the deviations do not pose a safety risk, and if agreed between the appointed Cardiologist and the investigator.

  8. Has vital signs outside of the following normal range at screening, Day -1 or Day 1 predose:

    1. Blood pressure (BP):

      Supine BP (after at least 5 minutes of supine rest):

      • Systolic blood pressure: 90 - 140 mmHg.
      • Diastolic blood pressure: 40 - 90 mmHg.
    2. Supine pulse rate after at least 5 minutes of rest: 45 - 100 bpm .
  9. Positive test for surface antigen (HBsAg), antibody (HCV Ab), or antibody (HIV Ab) at screening;
  10. Subjects who are pregnant, breast feeding or lactating.
  11. Any clinically relevant abnormal laboratory results (including hepatic and renal panels, complete blood count, chemistry panel, coagulation and urinalysis), and vital signs, or physical findings at screening, pre-dose of Day 1 (as judged by the investigator). In case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy subjects.
  12. Positive test results for alcohol or drugs of abuse at screening or Day -1.
  13. Presence or history of drug or alcohol abuse in the last 5 years, or the inability to refrain from alcohol use from 48 hours before screening, dosing and each scheduled visit until the end of the study. Alcohol abuse is defined as regular weekly intake of more than 14 units, using the following NHS alcohol tracker http://www.nhs.uk/Tools/Pages/drinks-tracker.aspx.
  14. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g., gum, patch, electronic cigarettes) within 3 months prior to the planned first day of dosing.
  15. Use of prescription medications within 14 days or 10 half-lives (whichever is longer) prior to Day 1 of the dosing period, or any over-the-counter (OTC) medication (including multivitamin, herbal, or homeopathic preparations, excluding hormonal , hormone-replacement therapy, and/or an occasional dose of acetaminophen) within 7 days prior to Day 1 of the dosing period.
  16. Consumption of herbal remedies or dietary supplements containing St. John's Wort in the three weeks before the planned Day 1 of the dosing period.
  17. Consumption of drugs or other substances known to be potent inhibitors or inducers of CYP P450s in the three weeks before the planned Day 1 of the dosing period. This includes food or drink products containing cranberry, pomegranate, star fruit, grapefruit, pomelos, exotic citrus fruits or Seville oranges (including marmalade and juices made from these fruits).
  18. Consumption of caffeine, caffeine-containing or xanthine-containing products, energy drinks containing taurine or glucuronolactone within 48 hours prior to the planned first study drug administration.
  19. Has received an investigational product or been treated with an investigational device within 90 days prior to first drug administration and will not start any other investigational product or device study within 90 days after last study drug administration.
  20. Known or suspected intolerance or hypersensitivity to the investigational product, any closely related compound or any of the stated ingredients.
  21. History of significant allergic reaction (anaphylaxis, angioedema) to any product (food, pharmaceutical, etc).
  22. Has donated or lost 400 mL blood or more within the last 16 weeks preceding the first day of dosing.
  23. Has a mental incapacity or language barriers precluding adequate understanding, co-operation, and compliance with the study requirements.

    Cassiopea S.p.A. CONFIDENTIAL 30 April 2018 Protocol Ref: CB-03-01/33 Final Version 5.0 Page 30 of 43 RPL Study No. C16021 C16021_Protocol_v5.0_30Apr2018

  24. An inability to follow a standardized diet and meal schedule or inability to fast, as required during the study.
  25. Prior screen failure (where the cause of the screen failure is not deemed to be temporary), randomization, participation, or enrolment in this study. Subjects who initially failed due to temporary non-medically significant issues are eligible for re-screening once the cause has resolved.
  26. Objection by the General Practitioner (GP) to the subject entering the study.
  27. Subjects with any medical history, conditions, or risks that, in the opinion of the investigator, may interfere with the subject's full participation in the study or compliance with the protocol, or may pose any additional risk for the subject or confound the assessment of the subject or outcome of the study.

    -

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Cortexolone 17α-propionate 7.5% solution

    Drug: Cortexolone 17α-propionate solution

  • Placebo comparator
    Vehicle solution

    Drug: Placebo

Interventions

  • Single topical application to be applied twice daily (0 hour and 12 hour) on Days 1-3 and Once Daily (0 hour) on Day 4.

  • DrugPlacebo

    matching placebo

06

What researchers measure

Primary outcomes

  1. PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)

    Cmax: Maximum observed plasma concentration Days 1 and 4

    Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.

  2. PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)

    tmax: Time of maximum observed plasma concentration

    Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.

  3. PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)

    t½: Apparent plasma terminal elimination half-life

    Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.

  4. PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)

    AUC0-24h: Area under the plasma concentration-time curve from time zero to 24 hours, calculated by the linear/log trapezoidal rule

    Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.

  5. PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)

    AUC0-t: Area under the plasma concentration-time curve from time zero up to the last quantifiable concentration

    Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.

  6. PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)

    AUC0-inf: Area under the plasma concentration-time curve from time zero to infinity

    Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.

  7. PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)

    CL: Blood clearance

    Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.

  8. PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)

    λz: Terminal elimination rate constant

    Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.

  9. PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)

    CLr: Renal clearance

    Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.

  10. PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)

    Vz: Volume of distribution

    Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.

  11. PK parameters of Cortexolone 17α-propionate and the two main metabolites Cortexolone 21-propionate (M1) and Cortexolone (M2)

    MRT: Mean residence time

    Time frame: Samples will be collected 1hour pre IMP administration and at 2, 3, 4, 5, 6, 7, 8, 9, 10,12 hours post IMP administration on Day1 and Day4. Further samples will be collected at 24 hours (Day 5) and 48 hours (Day 6) after the final dose on Day 4.

  12. QT interval changes

    QT intervals will be assessed using triplicate 12-lead ECGs electronically recorded at each time point and evaluated by a blinded select cardiologist

    Time frame: Day1 (each hour starting from 2 till 12 hours post IMP administration), Day 4 (each hour starting from 2 till 12 hours post IMP administration), Day 5 (24 hs post last IMP administration) and Day 6 (48 hs post last IMP administration).

Secondary outcomes

  1. Incidence of treatment-emergent adverse event

    Time frame: Day1, 2, 3, 4, 5, 6 and 14

  2. Proportion of subjects with skin reaction

    Skin reactions at the site of application will be assessed using a standardised in-house method. Any pain will be assessed using a Visual Analogue Scale (O-10).

    Time frame: Day1, 2, 3, 4, 5, 6 and 14 (if applicable)

  3. Proportion of subjects with clinically significant changes in laboratory safety tests (haematology, chemistry, coagulation and urinalysis)

    Time frame: Haematology, chemistry and coagulation: Day-1/1, 3, 5 and 14. Urinalysis: Day-1 and Day 14

  4. Proportion of subjects with abnormalities on electrocardiogram (ECG)

    Time frame: Day1, 4, 6 and 14

  5. Proportion of subjects with clinically significant changes in vital signs (systolic blood pressure, diastolic blood pressure, pulse rate and temperature)

    Time frame: Day1, 2, 3, 4, 5 and 14

07

Study locations

1 site
  • Richmond Pharmacology Ltd
    London, SW17 0RE, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Sep 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2018
First posted
Sep 11, 2018
StartActual
Jun 6, 2018
Primary completionActual
Sep 12, 2018
CompletionActual
Sep 12, 2018
Last update
Feb 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03665194
Lead sponsor
Cassiopea SpA
Responsible party
Sponsor
First posted
Sep 11, 2018
Start date
Jun 6, 2018
Primary completion
Sep 12, 2018
Completion
Sep 12, 2018
Last update
Feb 4, 2019

Study contacts

Jorg Taubel, MD FFPM
principal investigator · Richmond Pharmacology Limited

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion